Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Masahiro Endo"'
Autor:
Sayaka Ide, Takeshi Aramaki, Atsushi Urikura, Tsukasa Yoshida, Yoshihiro Nakaya, Masahiro Endo
Publikováno v:
Journal of Computer Assisted Tomography. 46:29-33
OBJECTIVE The aim of the study was to compare computed tomography (CT) angiography (CTA) imaging of deep inferior epigastric artery perforator (DIEP) using the ultrahigh-resolution CT (UHRCT) and conventional multidetector CT (MDCT). METHODS This ret
Autor:
Taichi Miyawaki, Tateaki Naito, Kosei Doshita, Hiroaki Kodama, Mikiko Mori, Naoya Nishioka, Yuko Iida, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Masahiro Endo, Kazuhisa Takahashi, Toshiaki Takahashi
Publikováno v:
Thoracic cancer. 13(14)
Cancer cachexia and tumor burden predict efficacies of programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors and chemotherapy or pembrolizumab in non-small cell lung cancer (NSCLC). There are no predictive models that simultaneo
Autor:
Yoshinobu Saito, Masafumi Sata, Yoshihiko Ito, Takahiko Sakamoto, Yuichiro Ohe, Noriyo Yanagawa, Masahiko Kusumoto, Shinichi Sasaki, Tomohisa Baba, Tae Iwasawa, Kazuyoshi Kuwano, Hiroaki Sugiura, Yutaka Fujiwara, Masahiro Endo, Terufumi Kato, Junya Tominaga, Fumikazu Sakai, Katsunori Oikado, Hirotsugu Kenmotsu
Publikováno v:
Cancer Science
Nivolumab can cause interstitial lung disease (ILD), which may be fatal; however, mortality risk factors have not been identified. This postmarketing study evaluated the poor prognostic factors of ILD in nivolumab‐treated patients with non–small
Autor:
Yuichiro Ohe, Masafumi Sata, Kazuyoshi Kuwano, Yoshinobu Saito, Tomohisa Baba, Masahiko Kusumoto, Tae Iwasawa, Yoshihiko Ito, Takahiko Sakamoto, Yutaka Fujiwara, Terufumi Kato, Noriyo Yanagawa, Shinichi Sasaki, Junya Tominaga, Hirotsugu Kenmotsu, Masahiro Endo, Katsunori Oikado, Fumikazu Sakai, Hiroaki Sugiura
Publikováno v:
Cancer Science
Nivolumab, a human monoclonal antibody against programmed death‐1, is approved for the treatment of non–small cell lung cancer (NSCLC). Although nivolumab is generally well tolerated, it can cause interstitial lung disease (ILD), a rare but poten
Autor:
Michitoshi Yabe, Haruyasu Murakami, Takahisa Kawamura, Taichi Miyawaki, Tateaki Naito, Eriko Miyawaki, Toshiaki Takahashi, Hirotsugu Kenmotsu, Hideyuki Harada, Kazushige Wakuda, Naoya Nishioka, Akira Ono, Masahiro Endo, Nobuaki Mamesaya, Shota Omori, Haruki Kobayashi, Hiroaki Kodama, Yasuhiro Gon
Publikováno v:
Lung Cancer. 151:60-68
Objectives Pembrolizumab is recommended for patients with previously untreated non-small cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of ≥1%. The KEYNOTE-024 study described the efficacy of pembroli
Autor:
Takuma Oishi, Takashi Sugino, Yoko Nakasu, Kazuaki Nakashima, Kensei Shirata, Masahiro Endo, Nakamasa Hayashi, Shoichi Deguchi, Koichi Mitsuya, Koji Muramatsu
Publikováno v:
Journal of Clinical Neuroscience. 69:43-50
We aimed to estimate the frequency of intratumoral susceptibility signals (ITSS) in susceptibility-weighted imaging (SWI) in consecutive patients with primary central nervous system lymphoma (PCNSL), and to determine if pretreatment heterogeneity of
Autor:
Tetsuya Mizuno, Mitsuhiro Isaka, Keiichi Ohshima, Haruki Kobayashi, Masatoshi Kusuhara, Hideaki Kojima, Kenichi Urakami, Yasuhisa Ohde, Tateaki Naito, Toshiaki Takahashi, Masakuni Serizawa, Ken Yamaguchi, Hayato Konno, Masahiro Endo, Takeshi Nagashima
Publikováno v:
Respirology (Carlton, Vic.)
Background and objective The efficacy expectation of immune checkpoint inhibitors against NSCLC in patients with ILD seems to be high because these populations are supposed to have high TMB. However, information about the characterization of TMB in p
Autor:
Naoya Nishioka, Eriko Miyawaki, Masahiro Endo, Shota Omori, Tateaki Naito, Kazuhisa Takahashi, Taichi Miyawaki, Haruki Kobayashi, Nobuaki Mamesaya, Haruyasu Murakami, Hideyuki Harada, Akira Ono, Ryo Ko, Hirotsugu Kenmotsu, Kazushige Wakuda, Toshiaki Takahashi, Keita Mori, Hiroaki Kodama
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Background Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI).
Autor:
Hayato Konno, Mitsuhiro Isaka, Tetsuya Mizuno, Hideaki Kojima, Toshiyuki Nagata, Takuya Kawata, Takashi Nakajima, Masahiro Endo, Yasuhisa Ohde
Publikováno v:
General thoracic and cardiovascular surgery. 70(5)
The lung is a major target organ of metastasis in several cancers. To distinguish primary lung cancer from pulmonary metastases is a clinical challenge. Small pulmonary nodules (PNs) are frequently diagnosed by frozen section diagnosis (FSD) intraope
Autor:
Toshiaki Takahashi, Hirotsugu Kenmotsu, Masaki Takinami, Masashi Niwakawa, Kazushige Wakuda, Shota Omori, Hirofumi Yasui, Haruyasu Murakami, Haruki Kobayashi, Masahiro Endo, Akira Ono, Takanori Kawabata, Nobuaki Mamesaya, Yoshio Kiyohara, Tateaki Naito
Publikováno v:
Investigational New Drugs
Background Immune-related hepatotoxicity is often regarded as immune-related hepatitis (irHepatitis) despite including immune-related sclerosing cholangitis (irSC). This study examined the clinical differences between irSC and irHepatitis.Methods A s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab541e14a9d8045ee3938739fb9f60bf
https://doi.org/10.21203/rs.3.rs-421221/v1
https://doi.org/10.21203/rs.3.rs-421221/v1